19
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología Translated title: Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

      research-article
      a , b , c , d , c , e , f , g , h , i , j , c , * , e , k , j , a
      Revista Espanola De Cardiologia
      Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Cardiología.
      ACOD, anticoagulantes orales de acción directa, AVK, antagonistas de la vitamina K, COVID-19, enfermedad infecciosa de 2019 por coronavirus, ETEV, enfermedad tromboembólica venosa, HBPM, heparina de bajo peso molecular, SARS-CoV-2, síndrome respiratorio agudo grave por coronavirus-2, COVID-19, coronavirus infectious disease-19, DOAC, direct action oral anticoagulant, LMWH, low–molecular-weight heparin, SARS-CoV-2, severe acute respiratory syndrome coronavirus-2, VKA, vitamin K antagonist, VTED, venous thromboembolic disease, COVID-19, Coronavirus, SARS-CoV-2, Trombosis, Antitrombóticos, COVID-19, Coronavirus, SARS-CoV-2, Thrombosis, Antithrombotics

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          RESUMEN

          La pandemia producida por la infección del nuevo coronavirus SARS-CoV-2, que da lugar a una enfermedad altamente contagiosa (COVID-19), ha producido un colapso de los sistemas sanitarios de todo el mundo. Se ha descrito que estos pacientes sufren un estado inflamatorio que condiciona un alto riesgo trombótico. Sin embargo, apenas hay información sobre cómo abordar el riesgo trombótico, la coagulopatía y el tratamiento anticoagulante de estos pacientes. Por otra parte, incluso los pacientes no infectados por COVID-19 sufren una tremenda influencia en su abordaje habitual por la situación sanitaria actual. El objetivo del presente documento, elaborado por el Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología, es presentar la información disponible y dar unas pautas sencillas de tratamiento con fármacos antitrombóticos.

          Translated abstract

          The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.

          Related collections

          Author and article information

          Contributors
          Journal
          Rev Esp Cardiol
          Rev Esp Cardiol
          Revista Espanola De Cardiologia
          Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Cardiología.
          0300-8932
          1579-2242
          22 April 2020
          22 April 2020
          Affiliations
          [a ]Instituto Cardiovascular, Hospital Clínico San Carlos, Madrid, España
          [b ]Servicio de Hematología, Hospital Universitario Morales Meseguer, Universidad de Murcia, Murcia, España
          [c ]Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBERCV, El Palmar, Murcia, España
          [d ]Servicio de Cardiología, Hospital General Universitario La Paz, CIBERCV, Madrid, España
          [e ]Servicio de Cardiología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Universidad Miguel Hernández, CIBERCV, Alicante, España
          [f ]Servicio de Cardiología, Hospital Arnau de Vilanova, Valencia, España
          [g ]Departamento de Medicina, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, Valencia, España
          [h ]Servicio de Cardiología, Hospital Universitario Son Llàtzer, Departamento de Medicina, Facultad de Medicina, Universidad de las Islas Baleares, Palma de Mallorca, España
          [i ]Servicio de Cardiología, Hospital General Universitario Santa Lucía, Cartagena, Murcia, España
          [j ]Servicio de Cardiología, Hospital Universitario de Bellvitge-IDIBELL, CIBERCV, L’Hospitalet de Llobregat, Barcelona, España
          [k ]Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, España
          Author notes
          [* ]Autor para correspondencia: Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Ctra. Madrid-Cartagena s/n, 30120 El Palmar, Murcia, España fcomarino@ 123456hotmail.com
          Article
          S0300-8932(20)30206-2
          10.1016/j.recesp.2020.04.006
          7176384
          32694078
          67c96bcc-7c27-4f5b-b920-e3ddbf80ec66
          © 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Cardiología.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 14 April 2020
          : 17 April 2020
          Categories
          Article

          acod, anticoagulantes orales de acción directa,avk, antagonistas de la vitamina k,covid-19, enfermedad infecciosa de 2019 por coronavirus,etev, enfermedad tromboembólica venosa,hbpm, heparina de bajo peso molecular,sars-cov-2, síndrome respiratorio agudo grave por coronavirus-2,covid-19, coronavirus infectious disease-19,doac, direct action oral anticoagulant,lmwh, low–molecular-weight heparin,sars-cov-2, severe acute respiratory syndrome coronavirus-2,vka, vitamin k antagonist,vted, venous thromboembolic disease,covid-19,coronavirus,sars-cov-2,trombosis,antitrombóticos,thrombosis,antithrombotics

          Comments

          Comment on this article